Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
20/20 Biolabs Inc. (AIDX) had Stock-Based Compensation of $0.50M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$0.73M |
|
$-2.75M |
|
$0.43M |
|
$0.30M |
|
$1.97M |
|
$-1.24M |
|
$-0.26M |
|
$-1.51M |
|
$-1.51M |
|
$-1.51M |
|
$-1.51M |
|
$-1.51M |
|
$-1.51M |
|
$-1.24M |
|
$-0.95M |
|
10.79M |
|
10.79M |
|
$-0.26 |
|
$-0.26 |
|
| Balance Sheet Financials | |
$5.08M |
|
$0.03M |
|
$1.05M |
|
$6.12M |
|
$2.55M |
|
-- |
|
$0.41M |
|
$2.96M |
|
$1.62M |
|
$2.17M |
|
$3.16M |
|
12.25M |
|
| Cash Flow Statement Financials | |
$-1.89M |
|
$-0.01M |
|
$5.43M |
|
$1.03M |
|
$4.55M |
|
$3.52M |
|
|
Stock-Based Compensation |
$0.50M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.99 |
|
-- |
|
-- |
|
-- |
|
-- |
|
41.71% |
|
-170.31% |
|
-170.31% |
|
-- |
|
-206.19% |
|
-376.78% |
|
$-1.89M |
|
-- |
|
-- |
|
-- |
|
0.12 |
|
3.84 |
|
2.51 |
|
35.91 |
|
-92.94% |
|
-69.46% |
|
-24.60% |
|
-47.68% |
|
$0.26 |
|
$-0.18 |
|
$-0.18 |
|